Nanaomycin E inhibits NLRP3 inflammasome activation by preventing mitochondrial dysfunction

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• The NLRP3 inflammasome is a key component of innate immunity, sensing cellular stress and activating inflammatory responses.
• Aberrant NLRP3 inflammasome activation is implicated in various inflammatory diseases, driving demand for targeted therapies.
• Nanaomycin A (NNM-A) is a known inhibitor of NLRP3 inflammasome activation.

Purpose of the Study:

• To investigate the anti-inflammatory potential of nanaomycin A derivatives, specifically nanaomycin E (NNM-E), against NLRP3 inflammasome activation.
• To elucidate the mechanism of action of NNM-E in inhibiting NLRP3 inflammasome.
• To evaluate the therapeutic efficacy of NNM-E in a preclinical model of skin inflammation.

Main Methods:

• In vitro assays measuring IL-1β and IL-18 release from macrophages.
• Assessment of ASC oligomerization and caspase-1 cleavage.
• Mitochondrial function and reactive oxygen species (ROS) production assays.
• In vivo study using an imiquimod-induced psoriasis-like skin inflammation model.

Main Results:

• Nanaomycin E (NNM-E) demonstrated potent inhibition of NLRP3 inflammasome activation, comparable to NNM-A but with significantly lower toxicity.
• NNM-E suppressed IL-1β and IL-18 release, ASC oligomerization, and caspase-1 cleavage.
• The compound mitigated mitochondrial damage and reduced ROS production, key upstream events in NLRP3 activation.
• NNM-E treatment effectively alleviated imiquimod-induced psoriasis-like skin inflammation in vivo.

Conclusions:

• Nanaomycin E (NNM-E) inhibits NLRP3 inflammasome activation by targeting mitochondrial dysfunction and reducing oxidative stress.
• NNM-E exhibits a favorable safety profile and demonstrates significant anti-inflammatory effects in a preclinical model.
• NNM-E represents a promising lead compound for the development of novel therapeutics for NLRP3 inflammasome-associated inflammatory diseases.